BRPI0916940A2 - peptídeos de epítopo de melk e vacinas contendo os mesmos. - Google Patents
peptídeos de epítopo de melk e vacinas contendo os mesmos.Info
- Publication number
- BRPI0916940A2 BRPI0916940A2 BRPI0916940A BRPI0916940A BRPI0916940A2 BR PI0916940 A2 BRPI0916940 A2 BR PI0916940A2 BR PI0916940 A BRPI0916940 A BR PI0916940A BR PI0916940 A BRPI0916940 A BR PI0916940A BR PI0916940 A2 BRPI0916940 A2 BR PI0916940A2
- Authority
- BR
- Brazil
- Prior art keywords
- epitope peptides
- vaccines containing
- melk
- melk epitope
- vaccines
- Prior art date
Links
- 101150054634 melk gene Proteins 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4251—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Dispersion Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8566308P | 2008-08-01 | 2008-08-01 | |
| PCT/JP2009/003630 WO2010013485A1 (en) | 2008-08-01 | 2009-07-30 | Melk epitope peptides and vaccines containing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0916940A2 true BRPI0916940A2 (pt) | 2015-11-24 |
Family
ID=41610195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0916940A BRPI0916940A2 (pt) | 2008-08-01 | 2009-07-30 | peptídeos de epítopo de melk e vacinas contendo os mesmos. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8674069B2 (enExample) |
| EP (1) | EP2321411B1 (enExample) |
| JP (1) | JP5816918B2 (enExample) |
| KR (1) | KR101705514B1 (enExample) |
| CN (1) | CN102171340B (enExample) |
| AU (1) | AU2009277811B2 (enExample) |
| BR (1) | BRPI0916940A2 (enExample) |
| CA (1) | CA2732721A1 (enExample) |
| DK (1) | DK2321411T3 (enExample) |
| ES (1) | ES2572367T3 (enExample) |
| IL (2) | IL210861A (enExample) |
| MX (1) | MX2011001194A (enExample) |
| SG (1) | SG193161A1 (enExample) |
| TW (1) | TWI466680B (enExample) |
| WO (1) | WO2010013485A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI466680B (zh) * | 2008-08-01 | 2015-01-01 | Oncotherapy Science Inc | Ｍｅｌｋ抗原決定位胜肽及含此胜肽的疫苗 |
| TWI485245B (zh) | 2010-01-25 | 2015-05-21 | Oncotherapy Science Inc | 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗 |
| US20150359864A1 (en) | 2012-03-09 | 2015-12-17 | Oncotherapy Science, Inc. | Pharmaceutical composition containing peptides |
| PT106590B (pt) | 2012-10-22 | 2015-01-20 | Secil S A Companhia Geral De Cal E Cimento S A | Mistura cimentícia branca ou colorida para fabrico de betão, argamassa e pastas interactivas, com propriedades fotoluminescentes |
| CN106117337B (zh) * | 2016-06-24 | 2020-02-11 | 安徽未名细胞治疗有限公司 | 一种特异性肿瘤抗原sf的ctl识别表位肽及其应用 |
| CN109890963B (zh) | 2016-08-31 | 2023-10-03 | 肿瘤疗法科学股份有限公司 | 针对melk的单克隆抗体及其使用 |
| KR102614437B1 (ko) * | 2021-02-03 | 2023-12-14 | 충북대학교 산학협력단 | 중년 남성 특이적 비만 또는 대사질환의 치료제로서 ｍｐｋ３８／ｍｅｌｋ의 신규 용도 |
| CN121064280A (zh) * | 2024-06-04 | 2025-12-05 | 复旦大学附属中山医院 | 一种抗肝癌hla-a*02型疫苗及其制备方法和应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100209784B1 (ko) | 1996-10-08 | 1999-07-15 | 박원훈 | 인간 단백질 변이인산화효소 유전자(hpk 38), 그의 염기 서열, 효소 단백질 및 그의 아미노산 서열 |
| US6229001B1 (en) * | 1997-01-03 | 2001-05-08 | Southern Research Institute | Mycobacterium fol a gene that encodes for the enzyme dihydrofolate reductase |
| US6605709B1 (en) * | 1999-04-09 | 2003-08-12 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Proteus mirabilis for diagnostics and therapeutics |
| AU2001269726A1 (en) | 2000-05-31 | 2001-12-11 | Chiron Corporation | Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
| US6833447B1 (en) * | 2000-07-10 | 2004-12-21 | Monsanto Technology, Llc | Myxococcus xanthus genome sequences and uses thereof |
| US20020156263A1 (en) | 2000-10-05 | 2002-10-24 | Huei-Mei Chen | Genes expressed in breast cancer |
| GB0103424D0 (en) * | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
| AU2003225535A1 (en) | 2002-01-31 | 2003-09-02 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cancer |
| KR20080045764A (ko) * | 2002-06-14 | 2008-05-23 | 신젠타 파티서페이션즈 아게 | 자일라나제, 이를 암호화하는 핵산, 및 이의 제조 및 사용방법 |
| TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
| WO2004070062A2 (en) | 2003-02-04 | 2004-08-19 | Wyeth | Compositions and methods for diagnosing and treating cancers |
| DK3170906T3 (en) | 2003-06-24 | 2018-11-05 | Genomic Health Inc | PREDICTION OF THE LIKELI REVENUE OF CANCER |
| EP1651956A4 (en) | 2003-08-14 | 2008-08-20 | Exelixis Inc | MELKS AS MODIFICATORS OF THE RAC ROUTE AND METHOD OF USE |
| WO2005073374A1 (ja) * | 2004-01-29 | 2005-08-11 | Dainippon Sumitomo Pharma Co., Ltd. | 新規腫瘍抗原蛋白質及びその利用 |
| JP5028601B2 (ja) | 2004-08-10 | 2012-09-19 | オンコセラピー・サイエンス株式会社 | 乳癌に関連する遺伝子およびポリペプチド |
| CA2580412A1 (en) * | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
| JP5109131B2 (ja) | 2005-02-10 | 2012-12-26 | オンコセラピー・サイエンス株式会社 | 膀胱癌を診断する方法 |
| US8088976B2 (en) * | 2005-02-24 | 2012-01-03 | Monsanto Technology Llc | Methods for genetic control of plant pest infestation and compositions thereof |
| CA2598889A1 (en) * | 2005-02-24 | 2006-08-31 | Cemines, Inc. | Compositions and methods for classifying biological samples |
| EP2305811A1 (en) | 2005-07-27 | 2011-04-06 | Oncotherapy Science, Inc. | Method of diagnosing smal cell lung cancer |
| JP5276846B2 (ja) * | 2005-09-13 | 2013-08-28 | 国立大学法人三重大学 | Ｔ細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞 |
| WO2008023841A1 (en) | 2006-08-25 | 2008-02-28 | Oncotherapy Science, Inc. | Breast cancer-associated gene, melk, and its interactions with bcl-g |
| TWI466680B (zh) | 2008-08-01 | 2015-01-01 | Oncotherapy Science Inc | Ｍｅｌｋ抗原決定位胜肽及含此胜肽的疫苗 |
-
2009
- 2009-07-29 TW TW98125493A patent/TWI466680B/zh not_active IP Right Cessation
- 2009-07-30 AU AU2009277811A patent/AU2009277811B2/en not_active Ceased
- 2009-07-30 DK DK09802730.3T patent/DK2321411T3/en active
- 2009-07-30 CA CA2732721A patent/CA2732721A1/en not_active Abandoned
- 2009-07-30 CN CN200980138900.XA patent/CN102171340B/zh active Active
- 2009-07-30 ES ES09802730T patent/ES2572367T3/es active Active
- 2009-07-30 BR BRPI0916940A patent/BRPI0916940A2/pt not_active IP Right Cessation
- 2009-07-30 WO PCT/JP2009/003630 patent/WO2010013485A1/en not_active Ceased
- 2009-07-30 EP EP09802730.3A patent/EP2321411B1/en active Active
- 2009-07-30 MX MX2011001194A patent/MX2011001194A/es active IP Right Grant
- 2009-07-30 SG SG2013057914A patent/SG193161A1/en unknown
- 2009-07-30 KR KR1020117004323A patent/KR101705514B1/ko not_active Expired - Fee Related
- 2009-07-30 US US13/056,598 patent/US8674069B2/en active Active
- 2009-07-30 JP JP2011504270A patent/JP5816918B2/ja active Active
-
2011
- 2011-01-25 IL IL210861A patent/IL210861A/en not_active IP Right Cessation
-
2014
- 2014-02-03 US US14/171,532 patent/US9193765B2/en active Active
- 2014-05-05 IL IL232461A patent/IL232461A0/en unknown
-
2015
- 2015-10-27 US US14/924,546 patent/US9675680B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2572367T3 (es) | 2016-05-31 |
| AU2009277811A8 (en) | 2011-03-03 |
| EP2321411B1 (en) | 2016-03-30 |
| CN102171340A (zh) | 2011-08-31 |
| DK2321411T3 (en) | 2016-06-06 |
| US9193765B2 (en) | 2015-11-24 |
| KR20110045018A (ko) | 2011-05-03 |
| US9675680B2 (en) | 2017-06-13 |
| IL210861A0 (en) | 2011-04-28 |
| US8674069B2 (en) | 2014-03-18 |
| JP5816918B2 (ja) | 2015-11-18 |
| SG193161A1 (en) | 2013-09-30 |
| MX2011001194A (es) | 2011-03-15 |
| US20110212115A1 (en) | 2011-09-01 |
| TWI466680B (zh) | 2015-01-01 |
| AU2009277811A1 (en) | 2010-02-04 |
| IL210861A (en) | 2015-02-26 |
| IL232461A0 (en) | 2014-06-30 |
| KR101705514B1 (ko) | 2017-02-10 |
| US20160101171A1 (en) | 2016-04-14 |
| US20140141028A1 (en) | 2014-05-22 |
| CA2732721A1 (en) | 2010-02-04 |
| JP2011529683A (ja) | 2011-12-15 |
| HK1156341A1 (zh) | 2012-06-08 |
| WO2010013485A1 (en) | 2010-02-04 |
| CN102171340B (zh) | 2016-12-21 |
| EP2321411A1 (en) | 2011-05-18 |
| TW201006486A (en) | 2010-02-16 |
| EP2321411A4 (en) | 2012-12-05 |
| AU2009277811B2 (en) | 2015-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0914782A2 (pt) | peptídeos de epítopos de cdca1 e vacinas contendo os mesmos | |
| PL2465864T3 (pl) | Szczepionki z peptydem pochodzącym z Eph4 | |
| EP2276499A4 (en) | ANTIGEN OF RECOMBINANT GLIADINE DEAMIDED | |
| PL2493925T3 (pl) | Białka wiążące antygen ludzkiej IL-23 | |
| BRPI0911604A2 (pt) | vacinas de polipeptídeo de flagelina | |
| DK2651436T3 (da) | Mycobakterie antigen sammensætning. | |
| BRPI1011005A2 (pt) | anticorpos anti-epcam | |
| HRP20150241T1 (xx) | Antikancerogeni fuzijski protein | |
| EP2377932A4 (en) | ANTI-Siglec-15 ANTIBODY | |
| BRPI1008887A2 (pt) | peptídeos de foxm1 e vacinas contendo os mesmo | |
| BRPI0915367A2 (pt) | peptídeos e epítopos anti-p2x7 | |
| IL232461A0 (en) | Melk epitope peptides and vaccines containing the same | |
| DK2114993T3 (da) | Vaccine | |
| DK3339865T3 (da) | Assay for jc-virus-antistoffer | |
| ME02224B (me) | Antikancerski fuzioni protein | |
| BR112012005389A2 (pt) | preparações pesticidas | |
| IL229926A (en) | Neil3 peptides and vaccines including the same | |
| BRPI0917391A2 (pt) | peptídeo de epítodo de hig2 e urlc10 e vacinas contendo o mesmo | |
| BRPI0921578A2 (pt) | vacinas unitemporais | |
| BRPI0919766A2 (pt) | peptídeo de epítopo de rab6kifl/kif20a e vacinas contendo o mesmo | |
| BRPI1013938A2 (pt) | "peptídeos ttk e vacinas incluindo os mesmos" | |
| BRPI1010666A2 (pt) | peptídeos de cdc45l e vacinas incluindo dos mesmos | |
| BR112013013158A2 (pt) | peptídeos de tomm34 e vacinas incluindo os mesmos | |
| BRPI0923402A2 (pt) | Peptídeos c10rf59 e vacinas incluindo os mesmos. | |
| BRPI1012312A2 (pt) | peptídeos vangl1 e vacinas incluindo os mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2473 DE 29-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |